Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 5/20 | 0.51 |
| ▸ | NMT2 | O60551 | 4/20 | 0.51 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | FURIN | P09958 | 4/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31031458 | 0.92 | NMT1 (0.49) | NMT1NMT2SLC15A2CTSLFURIN | |
| SCHEMBL30558181 | 0.92 | NMT1 (0.50) | NMT1NMT2SLC15A2FURINGRIN2D | |
| SCHEMBL30558189 | 0.91 | NMT1 (0.52) | NMT1NMT2SLC15A2FURINGRIN2D | |
| SCHEMBL30446798 | 0.90 | SLC15A2 (0.55) | NMT1NMT2SLC15A2SLC6A5TLR2 | |
| SCHEMBL29389004 | 0.88 | SLC15A2 (0.51) | NMT1NMT2SLC15A2CTSLFURIN | |
| SCHEMBL30288582 | 0.88 | GRIN2D (0.49) | NMT1NMT2SLC15A2CTSLGRIN2D | |
| SCHEMBL30089322 | 0.87 | SLC15A2 (0.47) | NMT1NMT2SLC15A2CTSLFURIN | |
| SCHEMBL3396651 | 0.87 | MME (0.45) | — | |
| SCHEMBL3396644 | 0.87 | MME (0.45) | — | |
| SCHEMBL31593363 | 0.86 | GRIN2D (0.48) | NMT1NMT2SLC15A2CTSLFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310521-A1 | COMBINATION COMPRISING BACILLUS AND AN ESSENTIAL OIL AND METHODS FOR MAKING AND USING | PHIBRO ANIMAL HEALTH CORPORATION (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023192262-A1 | A COMBINATION COMPRISING BACILLUS AND AN ESSENTIAL OIL AND METHODS FOR MAKING AND USING | PHIBRO ANIMAL HEALTH CORPORATION (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11723919-B2 | Composition or combination comprising anionic dietary supplement and 25-hydroxy vitamin D | PHIBRO ANIMAL HEALTH CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-11471490-B2 | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof | TORQUE THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220195071-A1 | IMMUNOTHERAPEUTIC COMPOSITIONS AND USE THEREOF | TORQUE THERAPEUTICS, INC. | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723919-B2 | Composition or combination comprising anionic dietary supplement and 25-hydroxy vitamin D | VDR, CYP24A1, GC | NMT1 4562/4885NMT2 4186/4885SLC15A2 727/4885 |
| US-20230310521-A1 | COMBINATION COMPRISING BACILLUS AND AN ESSENTIAL OIL AND METHODS FOR MAKING AND USING | CHIA, YBX3, XPA | NMT1 4077/4885NMT2 4404/4885SLC15A2 4448/4885 |
| US-20220195071-A1 | IMMUNOTHERAPEUTIC COMPOSITIONS AND USE THEREOF | IL2, CD47, IFNG | NMT1 3390/4885NMT2 3315/4885SLC15A2 3367/4885 |
| US-11471490-B2 | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof | CD4, ICOS, IL2 | NMT1 2221/4885NMT2 2112/4885SLC15A2 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.